11 results on '"Sinnott, Jennifer A"'
Search Results
2. Abstract A045: All happy families are alike: Transcriptomic homogeneity in indolent prostate tumors is a useful prognostic biomarker
- Author
-
Gerke, Travis, primary, Tyekucheva, Svitlana, additional, Creed, Jordan H., additional, Penney, Kathryn L., additional, Sinnott, Jennifer A., additional, Ebot, Ericka, additional, Berglund, Anders E., additional, Loda, Massimo, additional, Stampfer, Meir J., additional, Kraft, Peter, additional, Parmigiani, Giovanni, additional, and Mucci, Lorelei A., additional
- Published
- 2018
- Full Text
- View/download PDF
3. Abstract 5168: Tumor metabolism as a driver of lethal prostate cancer
- Author
-
Kelly, Rachel S., primary, Sinnott, Jennifer A., additional, Rider, Jennifer R., additional, Ebot, Ericka, additional, Gerke, Travis, additional, Penney, Kathryn, additional, Bowden, Michaela, additional, Loda, Massimo, additional, Kantoff, Philip W., additional, Martin, Neil E., additional, Giovannucci, Edward L., additional, Pettersson, Andreas Pettersson, additional, Tyekucheva, Svitlana, additional, Wilson, Kathryn M., additional, Vander Heiden, Matthew, additional, and Mucci, Lorelei A., additional
- Published
- 2015
- Full Text
- View/download PDF
4. Association of Prostate Cancer Risk Variants with Gene Expression in Normal and Tumor Tissue.
- Author
-
Penney, Kathryn L., Sinnott, Jennifer A., Tyekucheva, Svitlana, Gerke, Travis, Shui, Irene M., Kraft, Peter, Sesso, Howard D., Freedman, Matthew L., Loda, Massimo, Mucci, Lorelei A., and Stampfer, Meir J.
- Abstract
The article presents research on association of prostate cancer risk variants with gene expression in normal and tumor tissue. It mentions the generation of messenger ribonucleic acid (mRNA) expression data with the Affymetrix GeneChip Human Gene 1.0 ST microarray of the Physicians' Health Study and Health Professionals Follow-up Study participants. It concludes the association of risk variants with several genes of prostate cancer and lipid metabolism pathways.
- Published
- 2015
- Full Text
- View/download PDF
5. Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal ProstateCancer: A Prospective Study.
- Author
-
Ke Zu, Martin, Neil E., Fiorentino, Michelangelo, Flavin, Richard, Lis, Rosina T., Sinnott, Jennifer A., Finn, Stephen, Penney, Kathryn L., Jing Ma, Fazli, Ladan, Gleave, Martin E., Bismar, Tarek A., Stampfer, Meir J., Pollak, Michael N., Loda, Massimo, Mucci, Lorelei A., and Giovannucci, Edward
- Abstract
The article presents a study that investigated the association between phosphatase and tensin homolog (PTEN) expression and prostate cancer mortality. The study explored the potential effect modification by IGF-IR, a direct activator of the phosphoinositide-3-kinase (PI3K) pathway, and evaluated protein expression in tumor using tumor tissues.
- Published
- 2013
- Full Text
- View/download PDF
6. Genome-wide Association Study of Prostate Cancer Mortality.
- Author
-
Penney, Kathryn L., Pyne, Saumyadipta, Schumacher, Fredrick R., Sinnott, Jennifer A., Mucci, Lorelei A., Kraft, Peter L., Jing Ma, Oh, William K., Kurth, Tobias, Kantoff, Philip W., Giovannucci, Edward L., Stampfer, Meir J., Hunter, David J., and Freedman, Matthew L.
- Abstract
The article presents a genome-wide association study on the mortality of prostate cancer patients. For the study, researchers examined prostate cancer cases and cases of cancer survival of at least 10 years beyond their first diagnosis. They did not find a single nucleotide polymorphism (SNP) which reached genome-wide significance. They concluded that there are no variants that were significantly connected to prostate cancer mortality at a genome-wide level.
- Published
- 2010
- Full Text
- View/download PDF
7. Toll-like Receptor Signaling Pathway Variants and Prostate Cancer Mortality.
- Author
-
Stark, Jennifer R., Wiklund, Fredrik, Gronberg, Henrik, Schumacher, Fredrick, Sinnott, Jennifer A., Stampfer, Meir J., Mucci, Lorelei A., and Kraft, Peter
- Abstract
The article discusses a study which conducts time-to-event analyses of prostate cancer mortality for individual tagging single-nucleotide polymorphism (SNP) and haplotypes from genes in the Toll-like receptor pathway. It emphasizes the significance of studies of prostate cancer mortality due to risk factors for incidence and mortality may vary. It concludes that no associations are observed for common haplotypes and prostate cancer mortality.
- Published
- 2009
- Full Text
- View/download PDF
8. Gleason Grade Progression Is Uncommon.
- Author
-
Penney, Kathryn L., Stampfer, Meir J., Jahn, Jaquelyn L., Sinnott, Jennifer A., Flavin, Richard, Rider, Jennifer R., Finn, Stephen, Giovannucci, Edward, Sesso, Howard D., Loda, Massimo, Mucci, Lorelei A., and Fiorentino, Michelangelo
- Subjects
- *
PROSTATE cancer , *PROSTATE-specific antigen , *TUMOR antigens , *PROGNOSIS , *CELL differentiation - Abstract
Gleason grade is universally used for pathologic scoring of the differentiation of prostate cancer. However, it is unknown whether prostate tumors arise well differentiated and then progress to less differentiated forms or if Gleason grade is an early and largely unchanging feature. Prostate-specific antigen (PSA) screening has reduced the proportion of tumors diagnosed at advanced stage, which allows assessment of this question on a population level. If Gleason grade progresses as stage does, one would expect a similar reduction in high-grade tumors. We studied 1,207 Physicians' Health Study and Health Professionals Follow-up Study participants diagnosed with prostate cancer from 1982 to 2004 and treated with prostatectomy. We compared the distribution of grade and clinical stage across the pre-PSA and PSA screening eras. We re-reviewed grade using the ISUP 2005 revised criteria. The proportion of advanced stage tumors dropped more than six-fold, from the earliest period (12/1982-1/1993), 19.9% stage ≥T3, to the latest (5/2000-12/2004), 3% stage T, none T4. The proportion of Gleason score ≥8 decreased substantially less, from 25.3% to 17.6%. A significant interaction between stage and diagnosis date predicting grade (P = 0.04) suggests that the relationship between grade and stage varies by time period. As the dramatic shift in stage since the introduction of PSA screening was accompanied by a more modest shift in Gleason grade, these findings suggest that grade may be established early in tumor pathogenesis. This has implications for the understanding of tumor progression and prognosis, and may help patients diagnosed with lower grade disease feel more comfortable choosing active surveillance. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
9. Cholesterol Metabolism and Prostate Cancer Lethality.
- Author
-
Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson SO, Andrén O, Cerhan JR, Giovannucci EL, Mucci LA, and Rider JR
- Subjects
- Aged, Biomarkers, Tumor analysis, Biomarkers, Tumor metabolism, Humans, Male, Middle Aged, Prognosis, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Squalene Monooxygenase metabolism, Tissue Array Analysis, Cholesterol metabolism, Prostatic Neoplasms metabolism, Squalene Monooxygenase analysis
- Abstract
Cholesterol metabolism has been implicated in prostate cancer pathogenesis. Here, we assessed the association of intratumoral mRNA expression of cholesterol synthesis enzymes, transporters, and regulators in tumor specimen at diagnosis and lethal prostate cancer, defined as mortality or metastases from prostate cancer in contrast to nonlethal disease without evidence of metastases after at least 8 years of follow-up. We analyzed the prospective prostate cancer cohorts within the Health Professionals Follow-up Study (n = 249) and the Physicians' Health Study (n = 153) as well as expectantly managed patients in the Swedish Watchful Waiting Study (n = 338). The expression of squalene monooxygenase (SQLE) was associated with lethal cancer in all three cohorts. Men with high SQLE expression (>1 standard deviation above the mean) were 8.3 times (95% confidence interval, 3.5 to 19.7) more likely to have lethal cancer despite therapy compared with men with the mean level of SQLE expression. Absolute SQLE expression was associated with lethal cancer independently from Gleason grade and stage, as was a SQLE expression ratio in tumor versus surrounding benign prostate tissue. Higher SQLE expression was tightly associated with increased histologic markers of angiogenesis. Collectively, this study establishes the prognostic value of intratumoral cholesterol synthesis as measured via SQLE, its second rate-limiting enzyme. SQLE expression at cancer diagnosis is prognostic for lethal prostate cancer both after curative-intent prostatectomy and in a watchful waiting setting, possibly by facilitating micrometastatic disease. Cancer Res; 76(16); 4785-90. ©2016 AACR., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
10. Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer.
- Author
-
Martin NE, Gerke T, Sinnott JA, Stack EC, Andrén O, Andersson SO, Johansson JE, Fiorentino M, Finn S, Fedele G, Stampfer M, Kantoff PW, Mucci LA, and Loda M
- Subjects
- Aged, Cohort Studies, Enzyme Activation, Humans, Immunohistochemistry, Male, Prostatic Neoplasms enzymology, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology, RNA, Neoplasm genetics, Signal Transduction, Phosphatidylinositol 3-Kinases metabolism, Prostatic Neoplasms metabolism, RNA, Neoplasm biosynthesis
- Abstract
Unlabelled: Assessing the extent of PI3K pathway activity in cancer is vital to predicting sensitivity to PI3K-targeting drugs, but the best biomarker of PI3K pathway activity in archival tumor specimens is unclear. Here, PI3K pathway activation was assessed, in clinical tissue from 1,021 men with prostate cancers, using multiple pathway nodes that include PTEN, phosphorylated AKT (pAKT), phosphorylated ribosomal protein S6 (pS6), and stathmin. Based on these markers, a 9-point score of PI3K activation was created using the combined intensity of the 4-markers and analyzed its association with proliferation (Ki67), apoptosis (TUNEL), and androgen receptor (AR) status, as well as pathologic features and cancer-specific outcomes. In addition, the PI3K activation score was compared with mRNA expression profiling data for a large subset of men. Interestingly, those tumors with higher PI3K activation scores also had higher Gleason grade (P = 0.006), increased AR (r = 0.37; P < 0.001) and Ki67 (r = 0.24; P < 0.001), and decreased TUNEL (r = -0.12; P = 0.003). Although the PI3K activation score was not associated with an increased risk of lethal outcome, a significant interaction between lethal outcome, Gleason and high PI3K score (P = 0.03) was observed. Finally, enrichment of PI3K-specific pathways was found in the mRNA expression patterns differentiating the low and high PI3K activation scores; thus, the 4-marker IHC score of PI3K pathway activity correlates with features of PI3K activation., Implications: The relationship of this activation score to sensitivity to anti-PI3K agents remains to be tested but may provide more precision guidance when selecting patients for these therapies., (©2015 American Association for Cancer Research.)
- Published
- 2015
- Full Text
- View/download PDF
11. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.
- Author
-
Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, and Giovannucci E
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor genetics, Cohort Studies, Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Grading, PTEN Phosphohydrolase genetics, Prospective Studies, Prostatic Neoplasms pathology, Receptor, IGF Type 1 genetics, Treatment Outcome, Biomarkers, Tumor biosynthesis, PTEN Phosphohydrolase biosynthesis, Prostatic Neoplasms metabolism, Receptor, IGF Type 1 biosynthesis
- Abstract
Background: Loss of PTEN has been shown to be associated with aggressive behavior of prostate cancer. It is less clear that loss of PTEN also increases the risk of cancer mortality. We investigated the association between PTEN expression and prostate cancer mortality and the potential effect modification by IGF-IR, a direct activator of the phosphoinositide-3-kinase (PI3K) pathway., Methods: Protein expression in tumor was evaluated using tumor tissues obtained from 805 participants of the Physicians' Health and the Health Professionals Follow-up studies who were diagnosed with prostate cancer and underwent radical prostatectomy. Proportional hazard models were used to assess PTEN expression and its interaction with IGF-IR, in relation to lethal prostate cancer (cancer-specific death or distant metastases)., Results: Low PTEN expression was associated with an increased risk of lethal prostate cancer [HR, 1.7; 95% confidence interval (CI), 0.98-3.2; Ptrend = 0.04]. The association was attenuated after adjustment for Gleason grade, tumor stage, and prostate-specific antigen (PSA) at diagnosis. A significant negative interaction between PTEN and IGF-IR was found (Pinteraction = 0.03). Either reduction in PTEN or increase in IGF-IR expression was sufficient to worsen prognosis. Models including PTEN and IGF-IR expression offer additional predicting power to prostate cancer survival, compared to those only including demographic and clinical factors., Conclusions: Low PTEN protein expression significantly increases the risk of lethal prostate cancer, particularly when the IGF-IR expression remains at normal level., Impact: PTEN and IGF-IR expression in tumor are promising candidates for independent prognostic factors to predict lethal prostate cancer., (©2013 AACR.)
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.